FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, more specifically to a composition for reducing or preventing glycosaminoglycan (GAG) accumulation in one or more CNS (central nervous system) tissues of the subject suffering from mucopolysaccharidosis of IIIB type; it can be used in medicine. The obtained composition contains fusion protein including functional enzyme alpha-N-acetylglucosaminidase (Naglu), spacer peptide and peptide mark based on insulin-like growth factor II of the human (IGF-II) at a concentration from 25 mg/ml to 35 mg/ml.
EFFECT: invention can be used in effective therapy of mucopolysaccharidosis of IIIB type.
81 cl, 12 dwg, 6 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION AND METHOD OF PREVENTION AND TREATMENT OF LYSOSOMAL ENZYME DEFICIENCY IN SUBJECT WITH TYPE II MUCOPOLYSACCHARIDOSIS | 2023 |
|
RU2814280C1 |
| COMPOUND CONTAINING THERAPEUTIC ENZYME AND TRANSPORT ELEMENT CONNECTED TO EACH OTHER DIRECTLY OR BY USING LINKER | 2022 |
|
RU2811100C1 |
| METHODS AND COMPOSITIONS FOR DELIVERING THERAPEUTIC PROTEIN | 2019 |
|
RU2818779C2 |
| COMPOSITIONS AND METHODS FOR INTERNALIZATION OF ENZYMES | 2018 |
|
RU2806021C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING PEPTIDE VERSIONS, AND METHODS OF USING THEM | 2015 |
|
RU2729161C2 |
| METHODS OF TREATING TISSUE CALCIFICATION | 2015 |
|
RU2770698C2 |
| POLYVALENT MODULATORS OF REGULATORY T-CELLS | 2017 |
|
RU2769871C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| METHODS AND COMPOSITIONS FOR REDUCING IMMUNOGENICITY USING NON-DEPLETION B-CELL INHIBITORS | 2020 |
|
RU2821892C2 |
